Stefan Kloiber, MD

Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

  • 3Articles
  • 7.3KReads
  • 2015–2026Active
  • 44Collaborators
  • 27Citations

About

Stefan Kloiber, MD, is affiliated with the Institute of Medical Science and the Department of Psychiatry at the University of Toronto, as well as the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health. His publications focus on major depressive disorder, addiction, and posttraumatic stress disorder, including studies on cannabis abstinence effects in comorbid PTSD and cannabis use disorder, the application of artificial intelligence for personalized depression treatment, and clinical risk factors for weight gain during psychopharmacologic treatment of depression. His work frequently involves collaboration with co-authors such as Ahmed N. Hassan and Bernhard T. Baune.

Publications

JCP
Effects of Extended Cannabis Abstinence in Comorbid PTSD and Cannabis Use Disorder
Original Research

Effects of Extended Cannabis Abstinence in Comorbid PTSD and Cannabis Use Disorder

February 18, 2026

Participants who achieved abstinence reported significantly greater reductions in total PTSD symptom severity and symptom count compared to those who did not.
, , , et al
JCP
Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Clinical Decision Support System for Personalized Depression Treatment Selection and Management
Original Research

Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Clinical Decision Support System for Personalized Depression Treatment Selection and Management

August 27, 2025

This study provides preliminary evidence that longitudinal use of an AI-enabled clinical decision support system can improve outcomes in MDD.
, , , et al
JCP
Original Research

Clinical Risk Factors for Weight Gain During Psychopharmacologic Treatment of Depression: Results From 2 Large German Observational Studies

June 24, 2015

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe